Some Observations on Liv.52 in the Treatment of Infective Hepatitis and Cirrhosis of Liver


Lala Surajnandan Prasad, F.R.C.P. (Edin.), D.C.H. (Lond.), F.A.A.P. (Hon.) Professor and Head of the Department of Pediatrics, Patna University, and Kaleshwer Prasad, M.B.,B.S. (Patna) Post-graduate Student, Department of Pediatrics, Children’s Hospital, Patna Medical College Hospital, Patna, India.

MATERIAL AND METHODS

Seven cases of infective hepatitis and three cases of cirrhosis of the liver from the Hospital for Children, Patna Medical College Hospital, were included in his study. Thorough clinical examination was carried out before starting the trial of Liv.52, a product of The Himalaya Drug Co., containing Capparis spinosa (Kabra), Cichorium intybus (Kasni), Solanum nigrum (Makoi), Cassia occidentalis (Kasondi), Terminalia arjuna (Arjun), Achillea millefolium (Gandana), Tamarix gallica (Jhau).

Laboratory investigations were carried out in the Post-graduate Laboratory attached to the Department of Pediatrics, Patna University. The results of the trial are presented in the following tables.

Table 1: Showing Analysis of Cases of Infective Hepatitis and Cirrhosis

Type of case

No.

Age Range

Sex

Remarks

Male

Female

Cirrhosis of Liver

3

3-10 years

2

1

Advanced type of Cirrhosis

Infective Hepatitis

7

3-5 years

7

Nil

All with Jaundice and liver enlargement


Table 2: Showing Presenting Features in Cases of Infective Hepatitis

Presenting Features

No. of cases

Percentage

Pain abdomen

4

57%

Loss of appetite

7

100%

Jaundice

7

100%

Diarrhoea

4

57%

Low grade fever

6

85%

Liver enlargement

7

100%

Oedema of lower limbs

4

57%


Table 3: Showing Presenting Features in Cases of Cirrhosis

Presenting Features

No. of cases

Percentage

Ascites

3

100%

Oedema of lower limbs

2

66%

Haematemesis and Melena

2

66%

Jaundice

1

33%

Epistaxis

1

33%


Table 4 : Showing SGPT Serum Bilirubin before and after Liv.52 Therapy in Infective Hepatitis

Case No.

Type of Case

Serum bilirubin before therapy

SGPT Before therapy

Serum bilirubin after therapy

SGPT After therapy

1.

Infective hepatitis

3 mgm/100cc

45 Units/L

1.5 mgm/100cc

30 Units

2.

" "

3.5 mgm/100cc

42 Units/L

1.2 mgm/100cc

30 "

3.

" "

2.8 mgm/100cc

40 Units/L

0.8 mgm/100cc

40 "

4.

" "

1.8 mgm/100cc

30 Units/L

0.6 mgm/100cc

34 "

5.

" "

6.3 mgm/100cc

60 Units/L

1.3 mgm/100cc

30 "

6.

" "

4.8 mgm/100cc

68 Units/L

1.0 mgm/100cc

20 "

7.

" "

1.3 mgm/100cc

54 Units/L

1.0 mgm/100cc

48 "

8.

Cirrhosis of Liver

3.5 mgm/100cc

70 Units/L

0.8 mgm/100cc

30 "

9.

" "

1.3 mgm/100cc

80 Units/L

1.4 mgm/100cc

58 "

10.

" "

1.4 mgm/100cc

50 Units/L

1.5 mgm/100cc

30 "


Table 5 : Showing Results of Therapy after Liv.52 in Infective Hepatitis

Group No.

Dose of Liv.52

Duration of Treatment

Cured

Improved

Poor

Severe 4

½ T.S.F. t.d.s.

3 weeks

3

0

1

Moderate 2

½ T.S.F. t.d.s.

2 weeks

2

0

0

Mild 1

½ T.S.F. t.d.s.

1 week

1

0

0

The therapeutic results were assessed according to the following criteria :

Cured — Symptom-free, normal serum bilirubin and SGPT normal.

Improved — As above, but raised serum bilirubin and SGPT.

Poor — Persistence of symptoms, jaundice and raised serum bilirubin and SGPT.


Table 6 : Showing the Result of Therapy in Cirrhosis of Liver

Type of case

Good

Fair

Poor

Cirrhosis of Liver

3

1

1

1


SUMMARY

Seven patients suffering from infective hepatitis were treated with Liv.52 and they were divided into mild, moderate and severe groups according to the severity of clinical features and cases in each group were treated with half t.s.f. of Liv.52 thrice daily, with usual supportive medical treatment but none of them received corticosteroids.


Refference: http://www.himalayahealthcare.com/pdf_files/liv206.pdf
free delivery Liv 52
Copyrights © 2009 healthyliver.co.uk